Liver carcinoma, drug metabolism

Hepatic function impairment Amprenavir is principally metabolized by the liver exercise caution when administering this drug to patients with hepatic impairment. Carcinogenesis Results showed an increase in the incidence of benign hepatocellular adenomas and an increase in the combined incidence of hepatocellular adenomas plus carcinoma in males of both species at the highest doses tested. 

The small intestine is drained by the hepatic portal vein, making the liver the first port of call for orally absorbed drugs. Therefore, high hepatic metabolism will compromise systemic availability. Formulation to enhance lymphatic absorption offers the potential for avoiding such first-pass metabolism. It could also target anticancer agents to lymphatic carcinomas. Table 1 lists various materials and associated therapeutic agents that have been formulated for lymphatic delivery. 

---